Biotech Investing Buff Just Made $1.1 Billion Profit in 8 Months - Here's How

Biotech Investing
Dr. Patrick Soon-Shiong addresses delegates at the NHS Confederation Annual Conference. Photo by NHS Confederation, June 2014.

With a net worth of $12.6 billion, Patrick Soon-Shiong, MD, is the world's richest doctor, the richest American in the healthcare industry, and the 96th-richest person on the planet in 2015 according to Forbes.

And just in August, the 63-year-old became $1.1 billion richer -- from a move he'd made only eight months prior, according to Bloomberg...

You see, a vast source of Soon-Shiong's wealth comes from biotech investing. The son of Chinese immigrants to South Africa, Soon-Shiong founded two drug companies in the 1980s. He sold Abraxis and American Pharmaceutical Partners for a combined $9.1 billion. Currently, Soon-Shiong holds eight investments in these five biotech companies:

Date Invested In Round Details
Feb 4, 2015 Zoom $30M Series C Personal Investment
Oct 1, 2014 Keyssa $25M Series C NantWorks
Jul 18, 2014 NantMobile $30M Venture (Lead) Personal Investment
Nov 29, 2013 Fluential $2M Series A (Lead) Personal Investment
Sep 24, 2013 Zoom $6.5M Series B Personal Investment
Jun 6, 2013 Prizeo $2.5M Seed Personal Investment
Jul 1, 2011 Keyssa $5M Series B NantWorks
May 1, 2010 Keyssa $2M Series A NantWorks

*Data according to CrunchBase.

On Aug. 6, Soon-Shiong realized a $1.1 billion gain on an investment he'd made right before Christmas.

His company Cambridge Equities LP bought a 31% stake in biotech firm NantKwest Inc. (Nasdaq: NK) for $47 million on Dec. 23, 2014. The drugmaker focuses on cancer immunotherapy treatments.

It proved to be one of the biggest biotech initial public offerings (IPOs) in recent memory -- a holiday gift that kept on giving...

On July 28, NantKwest opened on the Nasdaq at $37 a share after floating 8.3 million shares at $25. That was well over the price talk of 7 million shares at $20-$23. It made the firm the largest biotech in the last decade, with an initial market cap of $2.6 billion, according to Renaissance Capital.

By Aug. 6, NK closed at $28.96 a share. According to Bloomberg Billionaires Index data (which assumes all shares were bought for the same price), that means Cambridge booked a ten-figure gain on its investment.

You Don't Have to Be Rich to Benefit from Biotech Investing

Soon-Shiong is capitalizing on a booming biotech sector.

But you don't have to be a billionaire to make money in the sector...

Even after a sell-off hit global markets hard on Aug. 24, the Nasdaq Biotechnology Index had gained 7.44% this year as of Aug. 25. That compares to a 9.28% downturn for the S&P 500 in the same period. And prior to "Black Monday," the biotech ETF was up more than 29% over the last 12 months, to the S&P's comparatively-paltry 0.81% climb.

Watch the following video for five easy steps to improve your biotech investing success. It'll show you how you can easily lower your risk and raise your profits immediately:

Related Articles:

aaaa